AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22975538 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 62
Study 22975538 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 62
Study 20171080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal magnesium sulphate 50 mg
Number of subjects: 60
Study 20171080 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mL of 0.9% sodium chloride (control group)
Number of subjects: 60
Study 18074471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (ivIgG) 0.6 g/kg body weight on day 0 and 0.3 g/kg body weight on day 1
Number of subjects: 653
Study 18074471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 653
Study 18074471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (ivIgG)
Number of subjects: 653
Study 16214045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tegafur (FT) 750 mg/m2/day for 21 days and leucovorin (LV) 15 mg/m2 every 8 h in cycles repeated every 28 days
Number of subjects: 237
Study 16214045 — intervention group
Group type: COMPARATOR
Intervention: Intravenous leucovorin (LV) 20 mg/m2 followed by 5-fluorouracil (5-FU) 425 mg/m2 daily for 5 days every 4 weeks for 2 cycles, and later every 5 weeks
Number of subjects: 237
Study 12085976 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (280 mg in pump prime)
Number of subjects: 64
Study 12085976 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 9972958 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin induced hypoglycemia
Number of subjects: 10
Study 9972958 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin releasing hormone (TRH) stimulation
Number of subjects: 10
Study 7751513 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lysine acetylsalicylate and furosemide (720 mg lysine acetylsalicylate and 40 mg furosemide twice daily)
Number of subjects: 9
Study 7751513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2283638 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglyol supplementation
Number of subjects: 11
Study 2283638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6118715 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and smoking cessation intervention
Number of subjects: 1232
Study 31856869 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on BASNEF model
Number of subjects: 120
Study 31856869 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 28341515 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support with the INFANT system
Number of subjects: 47062
Study 28341515 — intervention group
Group type: COMPARATOR
Intervention: No decision support
Number of subjects: 47062
Study 25872617 — intervention group
Group type: EXPERIMENTAL
Intervention: Untimed group (no time limit)
Number of subjects: 94
Study 25872617 — intervention group
Group type: COMPARATOR
Intervention: Timed group (15 minutes limit)
Number of subjects: 94
Study 23042808 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD 600 mg
Number of subjects: 48
Study 21336230 — intervention group
Group type: EXPERIMENTAL
Intervention: Message about benefits of male HPV vaccination
Number of subjects: 1178
Study 19739937 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir plus abacavir/lamivudine (arm A)
Number of subjects: 89
Study 19739937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine (arm B)
Number of subjects: 89
Study 17544889 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐VCM
Number of subjects: 95
Study 17544889 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 95
Study 16792054 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS e.max Press PCR
Number of subjects: 25
Study 16792054 — intervention group
Group type: COMPARATOR
Intervention: ProCAD PCR
Number of subjects: 25
Study 12682418 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU daily)
Number of subjects: 30
Study 12682418 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy non-smokers)
Number of subjects: 30
Study 10227944 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 30
Study 10227944 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional laparoscopy
Number of subjects: 30
Study 10227944 — intervention group
Group type: COMPARATOR
Intervention: Group A (Conventional then 3-D)
Number of subjects: 30
Study 10227944 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (3-D then Conventional)
Number of subjects: 30
Study 10227944 — intervention group
Group type: COMPARATOR
Intervention: Both inexperienced and experienced candidates
Number of subjects: 30
Study 8561064 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + exercise (n = 16)
Number of subjects: 41
Study 8561064 — intervention group
Group type: COMPARATOR
Intervention: Diet only (n = 13)
Number of subjects: 41
Study 8561064 — intervention group
Group type: COMPARATOR
Intervention: Diet only (n = 12)
Number of subjects: 41
Study 8561064 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Diet + exercise and Diet only)
Number of subjects: 41
Study 1899433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy
Number of subjects: 799
Study 1899433 — intervention group
Group type: COMPARATOR
Intervention: Minimal coronary lesion
Number of subjects: 799
Study 1899433 — intervention group
Group type: COMPARATOR
Intervention: Significant residual stenosis
Number of subjects: 799
Study 6871066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoctimine 50 mg
Number of subjects: 6
Study 6871066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoctimine 150 mg
Number of subjects: 6
Study 6871066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoctimine 250 mg
Number of subjects: 6
Study 6871066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31540617 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Stepped Alcohol Treatment (ISAT)
Number of subjects: 95
Study 31540617 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 95
Study 29260703 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of five beers
Number of subjects: 0
Study 26439559 — intervention group
Group type: EXPERIMENTAL
Intervention: FF+ (infant formula with scGOS/lcFOS and 30% fermented formula)
Number of subjects: 200
Study 26439559 — intervention group
Group type: COMPARATOR
Intervention: IF- (infant formula without fermented formula and scGOS/lcFOS)
Number of subjects: 200
Study 26439559 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants (reference group)
Number of subjects: 200
Study 23257991 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml kg(‐1) h(‐1) lactated Ringer's solution
Number of subjects: 100
Study 23257991 — intervention group
Group type: COMPARATOR
Intervention: 30 ml kg(‐1) h(‐1) lactated Ringer's solution
Number of subjects: 100
Study 21745239 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 41
Study 19929111 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16311773 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel tonsillectomy (HST)
Number of subjects: 280
Study 16311773 — intervention group
Group type: COMPARATOR
Intervention: Conventional steel tonsillectomy (CST)
Number of subjects: 280
Study 15324520 — intervention group
Group type: EXPERIMENTAL
Intervention: CIP/DEX (ciprofloxacin 0.3%/dexamethasone 0.1%) otic suspension, 3-4 drops twice daily for 7 days
Number of subjects: 468
Study 15324520 — intervention group
Group type: COMPARATOR
Intervention: N/P/H (neomycin 0.35%/polymyxin B 10,000 IU/mL/hydrocortisone 1.0%) otic suspension, 3-4 drops three times daily for 7 days
Number of subjects: 468
Study 10908255 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ‐123 (a selective ET(A) receptor antagonist; 100 nmol/min) in 0.9% saline, infused into the left coronary artery at a rate of 1 ml/min for 60 minutes
Number of subjects: 14
Study 10908255 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 14
Study 9302398 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration (12.5 or 18 micrograms/kg/day)
Number of subjects: 18
Study 9302398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9302398 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (75-90% maximum strength, 5-10 repetitions/set, 4 sets/day, 4 days/week)
Number of subjects: 18
Study 9302398 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training plus GH
Number of subjects: 18
Study 8094768 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (alteplase, rt-PA) 100 mg over 2 h followed by intravenous heparin
Number of subjects: 46
Study 8094768 — intervention group
Group type: COMPARATOR
Intervention: heparin alone
Number of subjects: 46
Study 8094768 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (alteplase, rt-PA)
Number of subjects: 46
Study 3950826 — intervention group
Group type: EXPERIMENTAL
Intervention: Similac With Iron
Number of subjects: 0
Study 3950826 — intervention group
Group type: EXPERIMENTAL
Intervention: Similac With Whey + Iron
Number of subjects: 0
Study 3950826 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30940404 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (20,000 IU of cholecalciferol once weekly for 24 weeks)
Number of subjects: 150
Study 30940404 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2:1 ratio)
Number of subjects: 150
Study 29797911 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with ibuprofen, methotrexate, and folic acid
Number of subjects: 56
Study 29797911 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment with ibuprofen, methotrexate, and folic acid
Number of subjects: 56
Study 29797911 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with western medicine
Number of subjects: 56
Study 27533265 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical therapy for upper limbs
Number of subjects: 35
Study 27533265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supervised physical therapy)
Number of subjects: 35
Study 25639496 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic fitness plus relaxation program (3 sessions per week for 2 months)
Number of subjects: 30
Study 25639496 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supervised exercise program)
Number of subjects: 30
Study 23338230 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain education plus telemonitoring
Number of subjects: 108
Study 23338230 — intervention group
Group type: COMPARATOR
Intervention: Pain education alone (control arm)
Number of subjects: 108
Study 21304082 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 891
Study 21304082 — intervention group
Group type: COMPARATOR
Intervention: Sentinel lymph node dissection (SLND) alone
Number of subjects: 891
Study 18924018 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg daily for one week
Number of subjects: 16
Study 18924018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18924018 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 16
Study 16424704 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose antithrombin III (30,000 IU intravenously over 4 days)
Number of subjects: 1008
Study 16424704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1008
Study 12661672 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory modality verification (e.g., BLENDER-loud)
Number of subjects: 0
Study 12661672 — intervention group
Group type: COMPARATOR
Intervention: Same modality verification (e.g., LEAVES-rustling)
Number of subjects: 0
Study 12661672 — intervention group
Group type: EXPERIMENTAL
Intervention: Different modality verification (e.g., CRANBERRIES-tart)
Number of subjects: 0
Study 12670811 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane plus fentanyl (Group B)
Number of subjects: 20
Study 12670811 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane plus fentanyl (Group A)
Number of subjects: 20
Study 10232637 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet group (35% energy deficit; n = 22)
Number of subjects: 67
Study 10232637 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + exercise group (35% net energy deficit; n = 22)
Number of subjects: 67
Study 10232637 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 23)
Number of subjects: 67
Study 8724152 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ablation zone (SA, 6.5 mm diameter)
Number of subjects: 75
Study 8724152 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipass multizone technique (MP, 3 zones)
Number of subjects: 75
Study 8724152 — intervention group
Group type: EXPERIMENTAL
Intervention: New software for three ablation zones in a single-pass (MZ)
Number of subjects: 75
Study 1684604 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical hand disinfection with handwashing (soap without antimicrobial additives) and 5-min disinfection with 60% n-propanol
Number of subjects: 0
Study 1684604 — intervention group
Group type: COMPARATOR
Intervention: Surgical hand disinfection with 1-min disinfection (without prior handwashing)
Number of subjects: 0
Study 1684604 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical hand disinfection with 5-min disinfection
Number of subjects: 0
Study 1684604 — intervention group
Group type: COMPARATOR
Intervention: Retaining surgical gloves during interoperative break
Number of subjects: 0
Study 1684604 — intervention group
Group type: COMPARATOR
Intervention: Removing surgical gloves during interoperative break
Number of subjects: 0
Study 6575575 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 tablets
Number of subjects: 387
Study 6575575 — intervention group
Group type: COMPARATOR
Intervention: Demoxytocin resoriblets
Number of subjects: 387
Study 30522577 — intervention group
Group type: EXPERIMENTAL
Intervention: PA program with a social adherence intervention (PASAI)
Number of subjects: 39
Study 30522577 — intervention group
Group type: COMPARATOR
Intervention: PA program
Number of subjects: 39
Study 30522577 — intervention group
Group type: EXPERIMENTAL
Intervention: PASAI program
Number of subjects: 39
Study 29305709 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 12
Study 29305709 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 12
Study 29305709 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 12
Study 26746876 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch is in the Bag intervention
Number of subjects: 633
Study 26746876 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 633
Study 24469936 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption during the follicular phase
Number of subjects: 24
Study 24469936 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 24
Study 24469936 — intervention group
Group type: COMPARATOR
Intervention: Placebo consumption
Number of subjects: 24
Study 23196556 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS of primary motor cortex (M1) for neuropathic pain
Number of subjects: 0
Study 23196556 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS of affected M1 for 'Kaifukuki' rehabilitation
Number of subjects: 0
Study 21305739 — intervention group
Group type: EXPERIMENTAL
Intervention: Molndal technique (Aquacel Ag‐Hydrofiber)
Number of subjects: 100
Study 21305739 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique (gauze compresses and hypoallergic adhesives)
Number of subjects: 100
Study 17225476 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg (Zol-20)
Number of subjects: 13
Study 17225476 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg (Zol-10)
Number of subjects: 13
Study 17225476 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg (Mel-5)
Number of subjects: 13
Study 17225476 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg (Mel-10)
Number of subjects: 13
Study 17225476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15771635 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ERT (CEE 0.3125 mg/day) + SSRI (fluvoxamine 50 mg/day) for 8 weeks
Number of subjects: 42
Study 15771635 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ERT (CEE 0.3125 mg/day) for 8 weeks
Number of subjects: 42
Study 12402196 — intervention group
Group type: EXPERIMENTAL
Intervention: Danaparoid (10 min after endotoxin)
Number of subjects: 30
Study 12402196 — intervention group
Group type: EXPERIMENTAL
Intervention: Danaparoid (3 h after endotoxin)
Number of subjects: 30
Study 12402196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9690334 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine ('Seroquel')
Number of subjects: 0
Study 9690334 — intervention group
Group type: COMPARATOR
Intervention: Usual-care antipsychotic medication
Number of subjects: 0
Study 7640409 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferative phase
Number of subjects: 30
Study 7640409 — intervention group
Group type: COMPARATOR
Intervention: Secretory phase
Number of subjects: 30
Study 2655835 — intervention group
Group type: EXPERIMENTAL
Intervention: Duoderm dressing
Number of subjects: 8
Study 2655835 — intervention group
Group type: COMPARATOR
Intervention: Omiderm dressing
Number of subjects: 8
Study 201958 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine conjugated oestrogens tablets (Premarin)
Number of subjects: 20
Study 201958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29411999 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional curing practices (7 days undisturbed + 21 days curing)
Number of subjects: 5
Study 28566028 — intervention group
Group type: EXPERIMENTAL
Intervention: Forensic Assertive Community Treatment (FACT)
Number of subjects: 70
Study 28566028 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 70
Study 26275649 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training for 1 hour, 6 days a week for 12 weeks
Number of subjects: 60
Study 26275649 — intervention group
Group type: COMPARATOR
Intervention: Brisk-walking with stretching exercise for 1 hour, 6 days a week for 12 weeks
Number of subjects: 60
Study 23917775 — intervention group
Group type: EXPERIMENTAL
Intervention: Empty phosphatidylcholine liposomes (PCL)
Number of subjects: 0
Study 23917775 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic bacterial lipoprotein and TLR1/2 agonist Pam(3)CSK(4) (BLP)
Number of subjects: 0
Study 23917775 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PCL and BLP
Number of subjects: 0
Study 23917775 — intervention group
Group type: COMPARATOR
Intervention: PCL
Number of subjects: 0
Study 21912481 — intervention group
Group type: EXPERIMENTAL
Intervention: Mushroom extract
Number of subjects: 30
Study 21912481 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 30
Study 21912481 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 30
Study 18312069 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM plus an educator-led didactic session
Number of subjects: 47
Study 18312069 — intervention group
Group type: COMPARATOR
Intervention: Didactic session alone
Number of subjects: 47
Study 16807414 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose N-acetylcysteine (600 mg IV bolus before angioplasty and 600 mg orally twice daily for 48 hours after angioplasty)
Number of subjects: 354
Study 16807414 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose N-acetylcysteine (1200 mg IV bolus and 1200 mg orally twice daily for 48 hours after intervention)
Number of subjects: 354
Study 16807414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 16807414 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall in-hospital mortality
Number of subjects: 354
Study 16807414 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose N-acetylcysteine
Number of subjects: 354
Study 16807414 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose N-acetylcysteine
Number of subjects: 354
Study 16807414 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint (death, acute renal failure requiring temporary renal-replacement therapy, or need for mechanical ventilation)
Number of subjects: 354
Study 12681523 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose modafinil (200 mg/day)
Number of subjects: 7
Study 12681523 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose modafinil (400 mg/day)
Number of subjects: 7
Study 12681523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 11382829 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO) at 2 atm abs and 2.8 atm abs
Number of subjects: 15
Study 9243352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous selegiline (0.5 mg)
Number of subjects: 16
Study 9243352 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral selegiline (0.5 mg)
Number of subjects: 16
Study 9243352 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral selegiline (1.0 mg)
Number of subjects: 16
Study 9243352 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral selegiline (1.5 mg)
Number of subjects: 16
Study 9243352 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral selegiline (5 mg)
Number of subjects: 16
Study 9243352 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral selegiline (10 mg)
Number of subjects: 16
Study 8491244 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 6 mg, administered orally once 12 hours before and once 12 hours after surgery
Number of subjects: 0
Study 3438580 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal muscle physiotherapy for 3 weeks
Number of subjects: 38